REFERENCES
  1. World Health Organization. (‎2021)‎. Cure All framework: WHO global initiative for childhood cancer: increasing access, advancing quality, saving lives. World Health Organization. https://apps.who.int/iris/handle/10665/347370 - Google Search.
  2. Reedijk AMJ, Coebergh JWW, de Groot-Kruseman HA, et al. Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015. Leukemia (2021);35(4):1001–1011.
  3. Abdelmabood S, Fouda AE, Boujettif F, & Mansour A. Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: high mortalities, early relapses, and poor survival. Jornal de Pediatria 2020; 96(1):108–116.
  4. Metzger ML, Howard SC, Fu LC, et al. outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet2003;362(9385):706–708.
  5. Mostert S, Sitaresmi MN, Gundy CM, Sutaryo, & Veerman AJP. Influence of socioeconomic status on childhood acute lymphoblastic leukemia treatment in Indonesia. Pediatrics 2006;118(6):1600-1606.
  6. Jabeen K, Ashraf MS, Iftikhar S, & Belgaumi AF. The Impact of Socioeconomic Factors on the Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) Treatment in a Low/Middle Income Country (LMIC).Journal of Pediatric Hematology/Oncology 2016; 38(8):587–596.
  7. Rubagumya F, Xu MJ, May L, et al. Outcomes of low-intensity treatment of acute lymphoblastic leukemia at Butaro Cancer Center of Excellence in Rwanda. Journal of Global Oncology 2018; 4:1–11.
  8. Kersten E, Scanlan P, Dubois SG, & Matthay KK. Current treatment and outcome for childhood acute leukemia in Tanzania. Pediatric Blood and Cancer 2013;60(12): 2047–2053.
  9. Olbara G, van der Wijk T, Njuguna F, et al. Childhood acute lymphoblastic leukemia treatment in an academic hospital in Kenya: Treatment outcomes and health-care providers’ perspectives.Pediatric Blood & Cancer 2021;68(12): e29366.
  10. Population, total - Kenya | Data. (n.d.). Retrieved January 27, 2023, from https://data.worldbank.org/indicator/SP.POP.TOTL?locations=KE - Google Search. (Retrieved January 31, 2023).
  11. Poverty: Development news, research, data | World Bank. (n.d.). Retrieved January 27, 2023, from https://www.worldbank.org/en/topic/poverty - Google Search. (Retrieved January 31, 2023).
  12. National Council for Population and Development; The State of Kenya Population 2020. https://www.unfpa.org/sites/default/files/admin resource/FINALPSAREPORT_0.pdf
  13. Barasa E, Rogo K, Mwaura N, & Chuma J. Kenya national hospital insurance fund reforms: Implications and lessons for universal health coverage. Health Systems and Reform 2018; 4(4):346–361.
  14. Veerman AJP, Hählen K, Kamps WA, et al. High Cure Rate with a Moderately Intensive Treatment Regimen in Non-High-Risk Childhood Acute Lymphoblastic Leukemia: Results of Protocol ALL VI from the Dutch Childhood Leukemia Study Group. Journal of Clinical Oncology 1996;14(3), 911–918.
  15. Arora RS, Pizer B, & Eden T. Understanding refusal and abandonment in the treatment of childhood cancer. Indian Pediatrics2010;47(12):1005–1010.
  16. Olbara G, Martijn HA, Njuguna F, et al. Influence of health insurance status on childhood cancer treatment outcomes in Kenya.Supportive Care in Cancer 2020;28(2):917–924.
  17. Ko RH, Ji L, Barnette P, et al. outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in childhood leukemia consortium study. Journal of Clinical Oncology 2010;28(4), 648–654.
  18. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 2008;111(12):5477-85.
  19. Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high-risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood 2015;126(8):964-71.
  20. Messinger Y, & Uckun FM. A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia. Leukemia and Lymphoma 1999;34(5–6):415–432.
  21. Hunger S, Reyes D, Negrin O, et al. Decreased early mortality and increased survival with less intensive therapy for acute lymphoblastic leukemia in the Dominican Republic. Pediatric Blood Cancer 2011 57(5):761-761
  22. Yeh TC, Liu HC, Hou JY, et al. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.Cancer , 2014;120(8):1255–1262.
  23. Burns JE, Pérez DR, Li Y, et al. Assessment of the impact of inpatient infectious events in pediatric patients with newly diagnosed acute leukemia at Dr. Robert Reid Cabral Children’s Hospital, Dominican Republic. PLOS ONE 2020;15(12): e0243795.
  24. Njuguna F, Martijn H, Langat S, et al. Factors influencing time to diagnosis and treatment among pediatric oncology patients in Kenya.Pediatr Hematol Oncol 2016;33(3):186-99.
  25. Kulkarni KP, & Marwaha RK. Symptom diagnosis interval in childhood acute lymphoblastic leukemia: Prognostic impact and association with clinico-demographic factors. Indian Journal of Medical and Paediatric Oncology 2012;33(03):188–188.
  26. Dai Q, Liu R, Wang Y, et al. Longer Time Intervals from Symptom Onset to Diagnosis Affect the Overall Survival in Children with Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 2022;44(6):285–292.
  27. Rivera GK, & Ribeiro RC. Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration, and partnerships. Expert Review of Hematology 2014;7(5):649-657.FIGURE LEGENDSFigure 1. Comparison of survival of children through the induction phase of therapy between the two cohorts before (n=136) and after (n=123) Figure 2. Comparison of treatment abandonment between the two cohorts before (n=136) and after (n=123) Figure 3: (A) Comparisons of event-free survival of children with low WBC (<50 x 109/L) to those with high WBC (>50 x 109/L), (B) comparison of event-free survival by age group. Figure 4: (A) comparisons of event-free survival estimates before (n=136) and after (n=123) (B) overall-survival estimates for the 2017-2020 cohort (n=123)
TABLE 1 Socio-demographic and clinical characteristics of patients for the two periods